Price Alert

Bicycle Therapeutics (BCYC)

NASDAQ: BCYC · Real-Time Price · USD

7.57

0.19 (2.57%)

At close: Aug 15, 2025, 1:07 PM

Bicycle Therapeutics Statistics

Share Statistics

Bicycle Therapeutics has 69.2M shares outstanding. The number of shares has increased by 0.38% in one year.

Shares Outstanding	69.2M
Shares Change (YoY)	0.38%
Shares Change (QoQ)	0.2%
Owned by Institutions (%)	60.31%
Shares Floating	61.51M
Failed to Deliver (FTD) Shares	57,114
FTD / Avg. Volume	20.51%

Short Selling Information

The latest short interest is 2.17M, so 3.14% of the outstanding shares have been sold short.

Short Interest	2.17M
Short % of Shares Out	3.14%
Short % of Float	5.98%
Short Ratio (days to cover)	7.22

Valuation Ratios

The PE ratio is -4.82 and the forward PE ratio is -1.74. Bicycle Therapeutics's PEG ratio is 0.05.

PE Ratio	-4.82
Forward PE	-1.74
PS Ratio	23.1
Forward PS	15.7
PB Ratio	1.03
P/FCF Ratio	-4.91
PEG Ratio	0.05

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Bicycle Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 13.81, with a Debt / Equity ratio of 0.01.

Current Ratio	13.81
Quick Ratio	13.81
Debt / Equity	0.01
Debt / EBITDA	-0.06
Debt / FCF	-0.06
Interest Coverage	-121.31

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$115.66K
Profits Per Employee	$-554.2K
Employee Count	305
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	-4.76M
Effective Tax Rate	2.74%

Stock Price Statistics

The stock price has increased by -67.64% in the last 52 weeks. The beta is 1.45, so Bicycle Therapeutics's price volatility has been higher than the market average.

Beta	1.45
52-Week Price Change	-67.64%
50-Day Moving Average	8
200-Day Moving Average	12.24
Relative Strength Index (RSI)	42.34
Average Volume (20 Days)	278,425

Income Statement

In the last 12 months, Bicycle Therapeutics had revenue of 35.27M and earned -169.03M in profits. Earnings per share was -0.29.

Revenue	35.27M
Gross Profit	28.11M
Operating Income	-209.87M
Net Income	-169.03M
EBITDA	-164.89M
EBIT	-172.07M
Earnings Per Share (EPS)	-0.29

Full Income Statement

Balance Sheet

The company has 879.52M in cash and 9.49M in debt, giving a net cash position of 870.03M.

Cash & Cash Equivalents	879.52M
Total Debt	9.49M
Net Cash	870.03M
Retained Earnings	-680.79M
Total Assets	883.89M
Working Capital	798.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -164.72M and capital expenditures -1.24M, giving a free cash flow of -165.96M.

Operating Cash Flow	-164.72M
Capital Expenditures	-1.24M
Free Cash Flow	-165.96M
FCF Per Share	-2.85

Full Cash Flow Statement

Margins

Gross margin is 79.7%, with operating and profit margins of -594.96% and -479.18%.

Gross Margin	79.7%
Operating Margin	-594.96%
Pretax Margin	-492.69%
Profit Margin	-479.18%
EBITDA Margin	-467.45%
EBIT Margin	-594.96%
FCF Margin	-470.47%

Dividends & Yields

BCYC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for BCYC is $23.5, which is 215% higher than the current price. The consensus rating is "Buy".

Price Target	$23.5
Price Target Difference	215%
Analyst Consensus	Buy
Analyst Count	11

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.34
Piotroski F-Score	4